array(25) {
["id"]=>
string(5) "79767"
["name"]=>
string(9) "邱海波"
["avatar"]=>
string(72) "https://img.39yst.com/uploads/19763/9a952aaaf654b20a328e19875c96cb69.jpg"
["status"]=>
string(1) "0"
["rank_type"]=>
string(1) "1"
["duodian_main_id"]=>
string(1) "0"
["miaopai"]=>
string(0) ""
["graphic_consult"]=>
string(1) "0"
["position"]=>
string(12) "主任醫(yī)師"
["introduction"]=>
string(8927) "一、基本情況
中山大學(xué)腫瘤醫(yī)院胃外科主診教授、主任醫(yī)師、博士生導(dǎo)師,曾作為聯(lián)合培養(yǎng)博士生留學(xué)于哈佛醫(yī)學(xué)院。擅長胃腸腫瘤外科治療,尤其是腹腔鏡、機(jī)器人微創(chuàng)手術(shù),曾多次在全國胃癌手術(shù)視頻大賽獲獎。主持國家自然基金、廣東省自然科學(xué)基金等科研項(xiàng)目,以第一/通訊作者在Cancer Commun, Cancer Res, JECCR等雜志發(fā)表了SCI論文40余篇。在ASCO 2024年會、ESMO 2024年會做口頭匯報。中國抗癌協(xié)會胃腸間質(zhì)瘤青年委員會副主任委員,CSCO胃腸間質(zhì)瘤、青年委員會專家委員會常委,CSCO翻譯小組副組長并擔(dān)任CSCO年會、BOA大會同聲傳譯?!栋┌Y》、《JCO》中文版等雜志編委。榮獲CSCO 35 under 35全國最具潛力腫瘤醫(yī)生獎項(xiàng)。獲得羊城好醫(yī)生、嶺南好醫(yī)生和廣州實(shí)力中青年醫(yī)生等稱號。
門診時間:周一上午、周四上午(越秀院區(qū));周一下午(黃埔院區(qū))。
?
二、教育及工作經(jīng)歷
教育經(jīng)歷
2010.10-2012.09 ?哈佛大學(xué)醫(yī)學(xué)院 聯(lián)合培養(yǎng)博士生
2009.09-2013.06 ?中山大學(xué) 腫瘤學(xué) 博士
2006.09-2009.06 ?中山大學(xué) 腫瘤學(xué) 碩士
2001.09-2006.06 ?廣州醫(yī)學(xué)院 臨床醫(yī)學(xué) 本科
?
工作經(jīng)歷
2024.01-至今 ?????中山大學(xué)腫瘤防治中心 胃外科 主任醫(yī)師
2018.01-2023.12???中山大學(xué)腫瘤防治中心 胃外科 副主任醫(yī)師
2016.01-2017.12???中山大學(xué)腫瘤防治中心 胃外科 主治醫(yī)師
2013.08-2015.12 ??中山大學(xué)腫瘤防治中心 胃胰科 醫(yī)師
?
三、學(xué)術(shù)兼職
中國抗癌協(xié)會胃腸間質(zhì)瘤青年委員會 副主任委員
CSCO 胃腸間質(zhì)瘤專家委員會?常務(wù)委員
CSCO 青年專家委員會?常務(wù)委員
?
四、主持科研項(xiàng)目
國家自然青年科學(xué)基金項(xiàng)目,81602061,JUN/Cyclin D1通路在胃腸間質(zhì)瘤對伊馬替尼耐藥的作用及機(jī)制研究,2017/01-2019/12,主持。
廣東省自然科學(xué)基金,面上項(xiàng)目,SALL1基因突變導(dǎo)致胃癌早發(fā)及腹膜轉(zhuǎn)移的現(xiàn)象與機(jī)制 ,2022/01-2024/12,主持。
國家自然科學(xué)基金面上項(xiàng)目,81372474、《抑制PREX2逆轉(zhuǎn)胃腸道間質(zhì)瘤對酪氨酸激酶抑制劑耐藥的研究》、2014/01-2017/12,第二參與人。
國家自然青年科學(xué)基金項(xiàng)目,81602143,TACC3介導(dǎo)肝癌射頻消融治療后轉(zhuǎn)移復(fù)發(fā)的機(jī)制與干預(yù)策略,2017/01-2019/12,第二參與人。
?
五、代表性論著
Haibo Qiu,?Sumei Cao?,?Ruihua Xu?, Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2021, Cancer Communications.?2021 Oct;41(10):1037-1048.
Xiayao Diao,?Yudong Ling,?Yi Zeng,?Yueqian Wu,?Chao Guo,?Yukai Jin,?Xiaojiang Chen,?Shoucheng Feng,?Jianrong Guo,?Chao Ding,?Feiyu Diao,?Zhicheng Du,?Shanqing Li,?Haibo Qiu*. Physical activity and cancer risk: a dose-response analysis for the Global Burden of Disease Study 2019. Cancer Communications.?2023 Nov;43(11):1229-1243.
Haibo Qiu,?Xu Zhang,?Jiali Qi,?Jiangwen Zhang,?Yin Tong,?Lei Li?,?Li Fu,?Yan-Ru Qin,?Xinyuan Guan,?Liyi Zhang. Identification and characterization of FGFR2+hematopoietic stem cell-derived fibrocytes as precursors of cancer-associated fibroblasts induced by esophageal squamous cell carcinoma. J Exp Clin Cancer Res.?2022 Aug 8;41(1):240.?
Chen W#,?Kuang Y#,?Qiu HB#,?Cao Z,?Tu Y,?Sheng Q,?Eilers G,?He Q,?Li HL,?Zhu M,?Wang Y,?Zhang R,?Wu Y1,?Meng F,?Fletcher JA,?Ou WB. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res.?2017 Sep 15;77(18):5107-5117.?
Li J#, Zhang J#, Zhang Y#, Qiu HB#,?Zhou Y, Zhou Y, Zhang X, Zhou Y, Zhu Y, Li Y, Wang M, Shen K, Tao K, Wu X, Wang H, Zhang B, Ling J, Ye Y, Wu X, Qu H, Ma Y, Jiao X, Zheng H, Jin J, Liu Z, Tan M, Fang Y, Zhang P, Zhang N, Lei C, Cai Z, Liang B, Peng Z, Huang Z, Dong J, Shen L. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.?Eur J Cancer. 2024 Jan:196:113439.
Haibo Qiu.?Complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases: results of a propensity score matching analysis from France. Cancer Communications.2019 Aug 8;39(1):45.
Haibo Qiu.?Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer. Cancer Communications. 2020;40:194–196.
Jianrong Guo, Shoucheng Feng, Hong Liu, Zhuopeng Chen, Chao Ding, Yukai Jin, Xiaojiang Chen, Yudong Ling, Yi Zeng, Hao Long,and Haibo Qiu*. TRIM6: An Upregulated Biomarker with Prognostic Significance and Immune Correlations in Gliomas. Biomolecules2023,13,1298.
Jianrong Guo, Shoucheng Feng, Hong Yu, Biyi Ou, Dan Jiang, Wei Zhuang, Chao Ding, Xiaojiang Chen, Miaoquan Zhang, Yudong Ling, Yi Zeng and Haibo Qiu*.?Transcriptomic study of gastrointestinal stromal tumors with liver metastasis.Front. Genet. 14:1007135. doi: 10.3389/fgene.2023.1007135
Miaoquan Zhang?#,?Chao Ding#?,?Lin Xu#?,?Biyi Ou?,?Shoucheng Feng,?Guoqiang Wang,?Wei Wang?,?Yao Liang,?Yingbo Chen,?Zhiwei Zhou,?Haibo Qiu*. Comparison of a Tumor-Ratio-Metastasis Staging System and the 8th AJCC TNM Staging System for Gastric Cancer. Front Oncol.?2021 Jul 8;11:595421.
Miaoquan Zhang?#?,?Chao Ding?#?,?Lin Xu?#?,?Shoucheng Feng?,?Yudong Ling,?Jianrong Guo,?Yao Liang,?Zhiwei Zhou,?Yingbo Chen,?Haibo Qiu*.A nomogram to predict risk of lymph node metastasis in early gastric cancer. Sci Rep.?2021 Nov 24;11(1):22873.
Zhang LY#, Wu JL#,?Qiu HB#, Dong SS, Zhu YH, Lee VH, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY, Fu L. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma.?Carcinogenesis. 2016 Mar;37(3):320-332.?
Wei Zhuang#, Jing‐Dun Xie#, Shan Zhou, Zhi‐Wei Zhou, Yi Zhou, Xiao‐Wei Sun, Xiu‐Hong Yuan, Min Huang, Si Liu, Shuang Xin, Qi‐Biao Su, HaiBo Qiu*, Xue‐Ding Wang*. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients??Cancer Med. 2018 Feb; 7(2): 317–324.
Qiu HB#,?Zhuang W#, Wu T, Xin S, Lin CZ, Ruan HL, Zhu X, Huang M, Li JL, Hou XY, Zhou ZW, Wang XD. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1.?Pharmacogenomics J. 2018 May 22;18(3):460-466.
?
國際大會報告
Haibo Qiu, Zhiwei Zhou, Ye Zhou,Jie Chen,Xiangbin Wan,Ning Li, Kaixiong Tao, Yong Li, Xin Wu, Zi Chen,Lihui Liu, Chen Yang, Lichuang Men, Hengbang Wang, Eric Liang,Cunlin Wang,Lixin Jiang, Dajun Yang, Yifan Zhai,and Ruihua Xu. Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma. ASCO annual meeting, Oral Presentation, June 2024.Chicago, US.
Haibo Qiu, Zhiwei Zhou, Ye Zhou, XiangBin Wan, Kaixiong Tao, Yong Li, Xin Wu, Lihui Liu, Zi Chen, Lichuang Men, Zhiyan?Liang, Ming Lu, Lixin Jiang, Dajun Yang, Yifan Zhai,Rui-hua Xu.Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST). ASCO, Poster discussion, June 2022.Chicago, US.?
Haibo Qiu. Palliative Surgical resection for patients with the advanced Gastrointestinal Stromal Tumor.?International Gastric Cancer Conference. Oral Presentation. April 2017 Beijing,?China.
?
論文摘要
Haibo?Qiu,?Zhongguo Zhou,?Xingyu Feng,?Xiaowei Sun,?Yingbo Chen,?Yuanxiang Guan,?Dazhi Xu,?Yuanfang Li,?Wei Li,?Youqing Zhan,?Rui-hua Xu,?Zhiwei Zhou. Results of long-term follow-up for patients with advanced gastrointestinal stromal tumor underwent palliative surgery after tyrosine kinase inhibitors therapy. Journal of Clinical Oncology?34, no.?15_suppl ??
Haibo?Qiu,?Wei Zhuang,?Ting Wu,?Min Huang,?Zhiwei Zhou,?Xueding Wang. Next generation sequencing (NGS) in wild type GISTs. Journal of Clinical Oncology?35, no.?15_suppl?
?
主編或編寫專著
CSCO胃腸間質(zhì)瘤診治指南, 中國臨床腫瘤學(xué)會,2023年,編委。
胃腸間質(zhì)瘤規(guī)范化外科治療中國專家共識,中國醫(yī)師協(xié)會,2018年,編委。
?
六、 獲獎及榮譽(yù)
2022 獲羊城好醫(yī)生,嶺南好醫(yī)生,廣州實(shí)力中青年醫(yī)生等稱號。
2021 大中華區(qū)胃癌手術(shù)視頻比賽 總決賽 冠軍
2017 CSCO最具潛力腫瘤醫(yī)生獎
2017 GIST-TOUR 全國研究設(shè)計比賽 冠軍
2012 獲教育部優(yōu)秀研究生學(xué)金
2012 中山大學(xué)優(yōu)秀博士生
?
?
?
更新時間:2024.10.12"
["adept"]=>
string(24) "胃癌、胃腸間質(zhì)瘤"
["duodian_doctor_id"]=>
string(6) "115125"
["source_from"]=>
string(12) "醫(yī)院官網(wǎng)"
["is_jingxuan"]=>
string(1) "0"
["title_num"]=>
string(0) ""
["created"]=>
string(10) "1754967839"
["doctor_title"]=>
string(12) "主任醫(yī)師"
["is_seniority"]=>
int(1)
["province_id"]=>
int(0)
["city_id"]=>
int(0)
["hospital_sort"]=>
string(2) "32"
["hospital"]=>
array(1) {
[0]=>
array(29) {
["id"]=>
string(5) "19763"
["name"]=>
string(30) "中山大學(xué)腫瘤防治中心"
["grade_id"]=>
string(1) "2"
["grade"]=>
string(0) ""
["type"]=>
string(1) "1"
["duodian_hospital_id"]=>
string(3) "814"
["address"]=>
string(27) "廣州市東風(fēng)東路651號"
["is_gongli"]=>
string(1) "1"
["logo"]=>
string(72) "http://pic.39yst.com/group2/M00/8B/F7/Co2PPWKfAdKACBy1AABiOqd-PC074.jpeg"
["is_pay"]=>
string(1) "0"
["pic"]=>
string(72) "http://pic.39yst.com/group2/M00/99/67/Co2PPWZ-H3qABl2PAAK_8SuU6HY43.jpeg"
["is_top100"]=>
string(1) "1"
["parent_areaid"]=>
string(2) "19"
["areaid"]=>
string(4) "1601"
["top100_sort"]=>
string(2) "32"
["guide"]=>
string(0) ""
["tel"]=>
string(38) "020-87673713,020-87765368 "
["is_seniority"]=>
string(1) "1"
["hospital_title"]=>
string(6) "三甲"
["hospital_grade_id"]=>
string(1) "2"
["hospital_type"]=>
string(12) "綜合醫(yī)院"
["hospital_type_id"]=>
string(1) "1"
["hospital"]=>
string(30) "中山大學(xué)腫瘤防治中心"
["department_id"]=>
string(1) "0"
["duodian_department_id"]=>
string(6) "213428"
["duodian_department_pid"]=>
string(6) "213407"
["department_name"]=>
string(0) ""
["hospital_department"]=>
string(9) "胃外科"
["duty"]=>
array(0) {
}
}
}
["version"]=>
int(40)
["isHaveSource"]=>
int(0)
["duty"]=>
string(0) ""
}